A Phase I Study of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 29 Feb 2016
At a glance
- Drugs Vorinostat (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Merck & Co
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Feb 2013 Planned end date changed from 1 Feb 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 27 Nov 2012 Planned end date changed from 1 Nov 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.